FDA Warns Against Using Off-Brand Versions of Weight Loss Drugs

FDA advises consumers not to use compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, as they may not be safe or effective.
Compounded drugs are not approved by the FDA, so their safety and effectiveness are not verified.
Ozempic and Wegovy, which contain semaglutide, pose risks to pregnancy and fetal health.
Doctors recommend patients stop taking semaglutide two to three months before trying to get pregnant.
Semaglutide mimics the hormone GLP-1 to trigger insulin production but also carries risks during pregnancy if not properly prescribed.